Cue Biopharma (Nasdaq: CUE) announced inducement equity awards on May 3, 2026, to seven new employees including newly appointed president and CEO Shao-Lee Lin, M.D., Ph.D. Grants include a non-statutory option for 655,074 shares and 327,537 RSUs for Dr. Lin, plus aggregate option grants of 518,599 shares and 327,534 RSUs to six other new employees. Options use an exercise price of $30.42 per share (May 1, 2026 close). Dr. Lin’s option vests monthly over four years; her RSUs were fully vested on grant. Other employees’ options vest quarterly over four years; their RSUs vested on grant.
Loading...
Loading translation...
Positive
Appointment of Shao-Lee Lin as president and CEO (leadership change)
Dr. Lin received 327,537 restricted stock units fully vested upon grant
Negative
Total non-statutory option grants equal 1,173,673 shares at $30.42 exercise price
Total restricted stock units awarded equal 655,071 shares fully vested upon grant
News Market Reaction – CUE
-2.04%
19 alerts
-2.04%Session close to close
+4.4%Peak Tracked
-18.8%Trough Tracked
$113.94MMarket Cap
0.1xRel. Volume
In the May 8 session, CUE declined 2.04%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +4.4% during that session.
Argus tracked a trough of -18.8% from its starting point during tracking.
Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
This announcement details inducement equity awards for Cue Biopharma’s new CEO and six other hires u...
Analysis
This announcement details inducement equity awards for Cue Biopharma’s new CEO and six other hires under the 2026 Inducement Stock Incentive Plan, including options and fully vested RSUs. It follows recent transformative steps: a private placement targeting about $30 million, a Phase 2 asset license, a 1-for-30 reverse split, and an effective $300,000,000 S-3 shelf. Investors may watch how these hires support clinical execution and future financing decisions under the new leadership.
Key Figures
Share price move:5.15%Shelf registration size:$300,000,000ATM capacity:$12,666,282+5 more
8 metrics
Share price move5.15%Price change in prior 24h before inducement grant news
Shelf registration size$300,000,000S-3 shelf registered March 17, 2026
ATM capacity$12,666,282At-the-market sales agreement under S-3
New hires covered7 employeesInducement equity awards granted May 3, 2026
CEO stock option655,074 sharesNon-statutory option at $30.42 exercise price
CEO RSUs327,537 sharesRestricted stock units, fully vested upon grant
Other employees’ options518,599 sharesAggregate non-statutory options for six new employees
Other employees’ RSUs327,534 sharesAggregate RSUs for six new employees, fully vested
New preclinical data on lead autoimmune candidate CUE-401 at IMMUNOLOGY2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent corporate, financing, and pipeline updates have often coincided with large positive price reactions, while the reverse split drew a modest decline.
Recent Company History
Over the past month, Cue Biopharma has reported multiple transformative events, including a 1-for-30 reverse split, a private placement targeting about $30 million, and an exclusive license for Phase 2 anti-IgE antibody Ascendant-221. The appointment of Shao-Lee Lin as CEO and preclinical CUE-401 data were accompanied by strong positive price moves. Today’s inducement grants tie directly to that leadership transition and the recently adopted 2026 Inducement Stock Incentive Plan referenced in an April 8-K.
"as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-statutory stock optionfinancial
"consisted of (i) a non-statutory stock option to purchase 655,074 shares of common stock"
A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.
restricted stock unitsfinancial
"and (ii) restricted stock units with respect to 327,537 shares of common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq capital marketregulatory
"which was the closing price of a share of the Company’s common stock on the Nasdaq Capital Market on May 1, 2026"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company’s 2026 Inducement Stock Incentive Plan and were unanimously approved by the independent directors of the Company as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants made to Dr. Lin consisted of (i) a non-statutory stock option to purchase 655,074 shares of common stock, at an exercise price of $30.42 per share, which was the closing price of a share of the Company’s common stock on the Nasdaq Capital Market on May 1, 2026, and (ii) restricted stock units with respect to 327,537 shares of common stock. Dr. Lin’s option will vest in equal, monthly installments over four years from her start date, subject to continued employment with the Company through each applicable vesting date. Dr. Lin’s restricted stock unit award was fully vested upon grant.
The inducement grants made to the six other new employees consisted of (i) non-statutory stock options to purchase an aggregate of 518,599 shares of common stock, at an exercise price of $30.42 per share, which was the closing price of a share of the Company’s common stock on the Nasdaq Capital Market on May 1, 2026, and (ii) restricted stock unit awards with respect to an aggregate of 327,534 shares of common stock. The option grants will vest in equal, quarterly installments over four years from each employee’s start date, subject to each employee’s continued employment with the Company through each applicable vesting date. The restricted stock unit awards were fully vested upon grant.
About Cue Biopharma Cue Biopharma (Nasdaq: CUE) is a clinical stage therapeutics company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
Investor and Media Contact ir@cuebio.com Cue Biopharma, Inc.
FAQ
What inducement awards did Cue Biopharma (CUE) grant to new CEO Shao-Lee Lin on May 3, 2026?
Dr. Lin received a non-statutory option for 655,074 shares and 327,537 RSUs. According to the company, the option exercise price was $30.42 and the RSUs were fully vested at grant.
How do Shao-Lee Lin’s option vesting terms work for Cue Biopharma (CUE)?
Dr. Lin’s option vests in equal monthly installments over four years from her start date. According to the company, vesting is subject to continued employment through each applicable vesting date.
What equity awards did the six other new Cue Biopharma (CUE) employees receive on May 3, 2026?
The six other employees received aggregate options for 518,599 shares and 327,534 RSUs. According to the company, those options vest quarterly over four years and the RSUs were fully vested upon grant.
What exercise price did Cue Biopharma (CUE) use for the May 3, 2026 inducement option grants?
The exercise price for all option grants was $30.42 per share. According to the company, $30.42 was the Nasdaq closing price on May 1, 2026.
What is the aggregate number of equity awards Cue Biopharma (CUE) granted to the seven new employees?
The grants total 1,173,673 option shares and 655,071 RSUs. According to the company, these figures cover the CEO plus six other new employees granted on May 3, 2026.
